Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.
In the digital age, personalized experiences have become essential. Whether in customer support, healthcare diagnostics, or content recommendations, people expect…